Utilization of <scp>EGFR</scp>, <scp>ALK,</scp> and <scp>BRAF</scp> Inhibitors in the Treatment of Lung Cancer in Germany
One twentieth of lung cancer patients diagnosed in 2016 in Germany received at least one EGFR, ALK, or BRAF inhibitor during follow-up. The proportion was higher in East than in West Germany. As the development and availability of new cancer drugs is a dynamic area, regularly updated utilization studies-ideally as cross-country-comparisons-are required.
Authors
- Ulrike Haug (ORCID: https://orcid.org/0000-0002-1886-2923)
- Nikolaj Rischke
- Josephine Kanbach
Institutions
- University of Bremen (DE)
- Leibniz Institute for Prevention Research and Epidemiology - BIPS (DE)
Publication Details
- Journal
- Cancer Reports
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/cnr2.70060
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- DAK-Gesundheit